FiercePharma10d
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood ...
Cure Today7d
P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia
P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the ...